BCL2 and breast cancer: Preclinical studies validated the use of BCL-2 inhibitors to enforce tumor cell death in human luminal breast cancer [7] justifying a Phase 1b Study of Bcl-2 inhibition with ABT-199 in combination with tamoxifen in metastatic ER-positive breast cancers (ISRCTN98335443).